

## 1 **Paracrine role for endothelial IGF-1 receptor in white adipocyte beiging**

2  
3 Natalie J Haywood<sup>1</sup>, Katherine I Bridge<sup>#1</sup>, Cheukyau Luk<sup>#1</sup>, Nele Warmke<sup>1,3</sup>, Katie J  
4 Simmons<sup>1</sup>, Michael Drozd<sup>1</sup>, Amy Moran<sup>1</sup>, Sam Straw<sup>1</sup>, Jason L Scragg<sup>1</sup>, Jessica Smith<sup>1</sup>,  
5 Sunti Limumpornpetch<sup>1</sup>, Claire H Ozber<sup>1</sup>, Chloe G Wilkinson<sup>1</sup>, Anna Skromna<sup>1</sup>, Natallia  
6 Makava<sup>1</sup>, Andrew Walker<sup>1</sup>, Nicole T Watt<sup>1</sup>, Romana Mughal<sup>1,4</sup>, Kathryn J Griffin<sup>1</sup>, Hema  
7 Viswambharan<sup>1</sup>, Nadira Y Yuldasheva<sup>1</sup>, David J Beech<sup>1</sup>, Piruthivi Sukumar<sup>1</sup>, Antonio Vidal-  
8 Puig<sup>2</sup>, Klaus K Witte<sup>1,5</sup>, Stephen B Wheatcroft<sup>1</sup>, Richard M Cubbon<sup>1</sup>, Lee D Roberts<sup>1</sup>, Mark  
9 T Kearney<sup>\*1</sup>.

10  
11 <sup>1</sup>. Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health,  
12 University of Leeds, UK.

13 <sup>2</sup>. University of Cambridge Metabolic Research Laboratories, Cambridge, UK.

14 <sup>3</sup>. Current address - Integrative Vascular Biology Laboratory, Max Delbrück Center for  
15 Molecular Medicine in the Helmholtz Association, Berlin, Germany.

16 <sup>4</sup>. Current address - Department of Optometry and Vision Sciences, University of Huddersfield,  
17 UK.

18 <sup>5</sup>. Current address - Dept of Internal Medicine I, University Clinic, RWTH Aachen University,  
19 Aachen, Germany.

20  
21 # These authors contributed equally

22 \*Corresponding author: [m.t.kearney@leeds.ac.uk](mailto:m.t.kearney@leeds.ac.uk)

### 23 24 **Acknowledgements**

25 We would like to acknowledge the histology service from the Division of Pathology and Data  
26 Analytics, Colorectal Pathology Trials, University of Leeds, for sectioning and staining adipose  
27 and liver samples. The Faculty of Biological Sciences Bioimaging Facility has received  
28 equipment grants from the Wellcome Trust to purchase confocal microscopes used in this  
29 project. MTK is the guarantor of this work and, as such, had full access to all the data in the  
30 study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

31  
32 NJH was funded by a British Heart Foundation Project Grant (PG/18/82/34120). CL was  
33 funded by a British Heart Foundation PhD studentship (FS/19/59/34896). MD was funded by  
34 a British Heart Foundation Clinical Research Training fellowship (FS/18/44/33792). NTW was  
35 funded by a British Heart Foundation Project Grant (PG/14/54/30939). LDR was funded by a  
36 Diabetes UK RD Lawrence Fellowship (16/0005382) and the Biotechnology and Biological  
37 Sciences Research Council (BB/R013500/1). SS is funded by a British Heart Foundation

38 Clinical Research Training Fellowship (FS/CRTF/20/24071). CHO and RMC were funded by  
39 British Heart Foundation Clinical Intermediate Fellowships (FS/12/80/29821). AS was funded  
40 by a British Heart foundation Programme grant (RG/15/7/31521). MTK holds a British Heart  
41 Foundation Chair in Cardiovascular and Diabetes research, which also funded NM and KJS  
42 (CH/13/1/30086).

43

#### 44 **Author contribution**

45 NJH, KIB, AS, NM and NYY performed in vivo experiments. NJH, KIB, NW, TS, AV and CHO  
46 performed ex vivo experiments. NJH, KIB, CL, KJS, AM, CHW and NTW performed cell culture  
47 and in vitro experiments. LDR performed metabolomic analysis. SS, JLS, JS, SL and KW  
48 obtained patient samples. NJH, KIB, CL, TS, AV, CHO and KG performed image and data  
49 analysis. NJH, MD and MTK wrote the manuscript. DJB, LDR and RMC reviewed the  
50 manuscript. DJB, PS, KKW, SBW, RMC and MTK obtained funding.

51

#### 52 **Declaration of Interests**

53 The authors declare no competing interests.

54

#### 55 **Summary**

56 There are at least two distinct types of thermogenic adipocyte in mammals: a pre-existing form  
57 established during development, termed classical brown adipocytes and an inducible form,  
58 'beige' adipocytes<sup>1-3</sup>. Various environmental cues can stimulate a process frequently referred  
59 to as 'beiging' of white adipose tissue (WAT), leading to enhanced thermogenesis and obesity  
60 resistance<sup>4,5</sup>. Whilst beiging of WAT as a therapeutic goal for obesity and obesity-related  
61 complications has attracted much attention<sup>6-9</sup>; therapeutics stimulating beiging without  
62 deleterious side-effects remain elusive<sup>10</sup>. The endothelium lines all blood vessels and is  
63 therefore in close proximity to all cells. Many studies support the possibility that the  
64 endothelium acts as a paracrine organ<sup>11-14</sup>. We explored the potential role of endothelial  
65 insulin-like growth factor-1 receptor (IGF-1R) as a paracrine modulator of WAT phenotype.  
66 Here we show that a reduction in endothelial IGF-1R expression in the presence of nutrient  
67 excess leads to white adipocyte beiging, increases whole-body energy expenditure and  
68 enhances insulin sensitivity via a non-cell autonomous paracrine mechanism. We  
69 demonstrate that this is mediated by endothelial release of malonic acid, which we show, using  
70 prodrug analogues, has potentially therapeutically-relevant properties in the treatment of  
71 metabolic disease.

72

73 **Keywords:** Endothelial cell, adipose tissue, IGF-1R, obesity, malonic acid, metabolomics.

74 Over the past four decades, changes in human lifestyle have contributed to a pandemic of  
75 nutritional obesity<sup>15</sup>. In simple terms, obesity occurs due to sustained elevation of calorie  
76 intake, most often in the form of lipid and carbohydrate, and/or a decline in energy  
77 expenditure<sup>16</sup>. Disruption of this 'energy balance equation'<sup>17</sup> can occur at any point in the  
78 human life course. In 2015, over 100 million children and 600 million adults were obese  
79 worldwide<sup>18</sup>. An unfavourable deviation in the energy balance equation in favour of calorie  
80 excess results in ectopic deposition of lipids in tissues such as the liver and skeletal muscle,  
81 which are ill-equipped to deal with this challenge. As a result, deleterious perturbations in  
82 cellular function lead to type 2 diabetes mellitus, accelerated cardiovascular disease, fatty liver  
83 and some cancers (<sup>19</sup> for review).

84

85 Dietary lipids are stored in adipose tissue (AT) of which broadly speaking, there are two types.  
86 White AT (WAT) specialised for the storage of energy in the form of triglyceride during nutrient  
87 excess undergoes expansive remodelling with adipocytes adopting a  
88 hypertrophic/hyperplastic phenotype<sup>20</sup>. The second form of AT is brown AT (BAT)<sup>21</sup>. BAT,  
89 unlike WAT, expresses the mitochondrial carrier protein uncoupling protein-1 (UCP-1). UCP-  
90 1 uncouples cellular respiration from mitochondrial ATP synthesis, affording BAT the capacity  
91 to oxidise lipids and glucose to generate heat<sup>21</sup>.

92

93 Recent studies indicate that at least two distinct types of thermogenic adipocyte exist in  
94 mammals: a pre-existing form established during development, termed 'classical brown', and  
95 an inducible form described as 'beige'<sup>4,5</sup>. BAT depots, previously thought to be limited to  
96 neonates, have also been identified in human adults<sup>1,2,3</sup>. Beige adipocyte biogenesis can be  
97 stimulated by various environmental cues, such as chronic cold exposure, <sup>4,5</sup> in a process  
98 frequently referred to as 'beiging' of WAT. The potentially favourable metabolic effects of  
99 inducing more thermogenic AT in response to nutrient excess, has led investigators to seek  
100 new approaches to stimulate WAT beiging.

101

102 The insulin/insulin-like growth factor-1 (IGF-1) signalling system evolved millions of years ago  
103 to co-ordinate organismal growth and metabolism. During evolution the insulin receptor (IR)  
104 and IGF-1 receptor (IGF-1R) diverged from a single receptor in invertebrates, into a more  
105 complex system in mammals consisting of the IR, IGF-1R and their respective ligands; insulin,  
106 IGF-1 and IGF-II (<sup>22</sup> for our review). We have previously shown that during calorie excess  
107 circulating IGF-1 increases and IGF-1R levels decline, in a range of tissues including the  
108 vasculature <sup>23,24</sup>.

109 The endothelium lines all blood vessels, and emerging data support the possibility that the  
110 endothelium acts as a paracrine organ<sup>11-14</sup>, including, endothelial to AT signalling<sup>25-27</sup>.  
111 Therefore, we explored the role of endothelial IGF-1R as a paracrine modulator in the  
112 pathophysiology of obesity, and identified a novel, small molecule mediated beiging  
113 mechanism.

114

## 115 **Results**

### 116 *Murine endothelial IGF-1R knockdown enhances whole-body insulin sensitivity during positive* 117 *energy balance*

118 To investigate the role of endothelial IGF-1R in the setting of increased energy balance, we  
119 generated a tamoxifen-inducible, endothelial cell-specific IGF-1R knockdown mouse (ECIGF-  
120 1R<sup>KD</sup>) (Figure 1A-B) with an mTmG reporter to confirm spatially appropriate Cre-recombinase  
121 activity (Supplementary figure 1A-C). When unchallenged on a standard laboratory chow diet  
122 or challenged with high fat diet (HFD) for two weeks, ECIGF-1R<sup>KD</sup> mice exhibited no difference  
123 in body (Figure 1C) or organ weight (Figure 1D). Glucose tolerance was also unchanged in  
124 both chow and HFD fed mice (Figure 1E-F). Insulin sensitivity was similar in chow fed-mice  
125 (Figure 1G), but was enhanced in ECIGF-1R<sup>KD</sup> after HFD feeding for two weeks, compared to  
126 wildtype littermates on the same diet (Figure 1H&I). After two weeks HFD, ECIGF-1R<sup>KD</sup> mice  
127 had similar core body temperature (Supplementary Figure 2A) and fasting plasma  
128 concentrations of glucose, insulin, IGF-I, free fatty acids, triglycerides, and leptin as wildtype  
129 littermates on the same diet (Supplementary figure 2B-G).

130

### 131 *Endothelial IGF-1R knockdown prevents deleterious remodelling of adipose tissue in the* 132 *setting of increased energy balance*

133 Historically, WAT was thought to be a simple storage depot for lipid. However, over the past  
134 two decades, research has revealed WAT to be a complex and plastic organ (Reviewed <sup>28</sup>).  
135 Targeting AT phenotype to mitigate against the adverse sequelae of obesity has thus received  
136 significant attention (Reviewed <sup>29</sup>). Mechanisms of changing WAT from a storage to  
137 thermogenic phenotype has been of particular interest <sup>6-9</sup>.

138

139 After two weeks of HFD, ECIGF-1R<sup>KD</sup> mice displayed increased energy expenditure in relation  
140 to body mass (Figure 2A), with no change in food intake or physical activity (Supplementary  
141 figure 3A-F) compared to wildtype littermates. Epididymal WAT from ECIGF-1R<sup>KD</sup> mice had  
142 smaller adipocytes (Figure 2B-D), increased vascularity (Figure 2E&F) and enhanced *ex vivo*  
143 sprouting angiogenesis (Figure 2G&H, Supplementary Figure 4A). This remodelling is  
144 contrary to the deleterious phenotype in humans with either a high body mass index or raised  
145 HbA1c (Supplementary figure 5A-I). ECIGF-1R<sup>KD</sup> mice had similar levels of epididymal WAT

146 fibrosis, lipid accumulation in the liver and interscapular BAT (Supplementary figure 6A-F).  
147 Vascularity in other AT depots (BAT, subcutaneous WAT and perinephric WAT) was  
148 unchanged (Supplementary figure 6G-L), as well as vascularity of other organs including liver  
149 and muscle (Supplementary figure 6M-P), suggesting an epididymal WAT specific effect of  
150 reduced endothelial IGF-1R. Chow fed ECIGF-1R<sup>KD</sup> mice had similar AT vascularity  
151 (Supplementary figure 7A&B), indicative of a specific response to over nutrition. When fed  
152 HFD for 2-weeks, ECIGF-1R<sup>KD</sup> also exhibited higher circulating levels of the beneficial  
153 adipokine adiponectin (Figure 2I), an endogenous insulin sensitizer. Epididymal WAT from  
154 HFD-fed ECIGF-1R<sup>KD</sup> also exhibited a change in gene expression including upregulation of  
155 *Ucp-1*, *Vegfa* and *Cited1* (Figure 2J), indicative of adipocyte beiging, which was not seen in  
156 chow-fed mice (Supplementary figure 7C).

157  
158 As discussed above, at least two types of thermogenic adipocyte exist in mammals, BAT and  
159 inducible 'beige' AT<sup>1-3</sup>. Beige adipocyte biogenesis may be stimulated by various  
160 environmental cues <sup>4,5</sup>, a process referred to as 'beiging'. Here we show that a reduction in  
161 endothelial IGF-1R expression in the presence of nutrient excess increases beige AT,  
162 increases whole-body energy expenditure, and enhances insulin sensitivity.

163  
164 To explore the chronicity of these findings, a separate cohort of ECIGF-1R<sup>KD</sup> mice and wildtype  
165 littermate controls received HFD for eight weeks. ECIGF-1R<sup>KD</sup> mice maintained endothelial  
166 IGF-1R knockdown (Supplementary figure 8A&B); body weight, organ weight, core body  
167 temperature and glucose tolerance were similar to wildtype littermate controls (Supplementary  
168 figure 8C-H). The enhanced insulin sensitivity of ECIGF-1R<sup>KD</sup> seen at 2 weeks HFD persisted  
169 after 8 weeks of HFD (Supplementary figure 8I-J). Circulating insulin and IGF-1 concentrations  
170 were unchanged (Supplementary figure 8K-L). Epididymal WAT from ECIGF-1R<sup>KD</sup> mice after  
171 eight weeks HFD still had smaller adipocytes (Supplementary figure 9A&B). ECIGF-1R<sup>KD</sup> mice  
172 also had reduced lipid accumulation in BAT (Supplementary figure 9C&D). There was no  
173 longer a difference in WAT vascularity (Supplementary figure 9E&F); however, increased *Vegf*  
174 and *Ucp-1* gene expression was retained (Supplementary figure 9G). There was no difference  
175 in WAT collagen deposition (Supplementary figure 9H-I) or fatty liver in ECIGF-1R<sup>KD</sup> mice after  
176 8 weeks HFD compared to wildtype littermate controls (Supplementary figure 9J&K). Taken  
177 together, these findings suggest that the advantageous effects of EC IGF-1R knockdown on  
178 insulin sensitivity and AT phenotype are retained over longer periods of HFD.

179  
180 *Endothelial IGF-1R knockdown modifies paracrine modulation of adipocyte function*

181 To probe mechanisms underpinning the favourable changes to WAT in ECIGF-1R<sup>KD</sup> mice  
182 receiving HFD, we investigated the possibility that adipocytes were directly derived from

183 ECIGF-1R<sup>KD</sup> endothelial cells, as it has been demonstrated that adipocytes of endothelial  
184 origin exist in BAT and WAT<sup>30</sup>. However, in our model, Cre activity in ECIGF-1R<sup>KD</sup> resulted in  
185 vascular GFP expression, as intended, but no GFP expressing adipocyte like structures were  
186 observed after 2 weeks of feeding, suggesting EC to AT transformation was not occurring  
187 (Supplementary Figure 10A).

188

189 Since studies continue to emerge supporting the endothelium as a paracrine organ<sup>11-14</sup>, we  
190 investigated a potential paracrine mechanism facilitating cross talk between the endothelium  
191 and WAT. Treatment of primary human adipocytes with conditioned media from primary EC  
192 of ECIGF-1R<sup>KD</sup> fed HFD for two weeks led to increased *UCP-1*, *CIDEA*, *PGC1a*, *CYCS* and  
193 *CD137* gene expression compared to adipocytes cultured in conditioned media from wildtype  
194 littermates fed HFD for two weeks (Supplementary Figure 10B). *UCP-1* and *CIDEA* expression  
195 induced by ECIGF-1R<sup>KD</sup> EC conditioned media was preserved following protein denaturation  
196 by boiling, suggesting a non-protein signal (Supplementary Figure 10C). We used a  
197 metabolomic approach to compare the small molecule secretome of EC from ECIGF-1R<sup>KD</sup>  
198 mice and their littermate controls after two weeks of HFD and found distinct differences in the  
199 small molecule endothelial secretome (Supplementary figure 11A). To our knowledge this is  
200 the first study to demonstrate the potential importance of the endothelial small molecule  
201 secretome in the pathophysiology of obesity.

202

203 *Malonic acid is a novel adipose tissue beiging metabokine*

204 A screen of the upregulated metabolites released from ECIGF-1R<sup>KD</sup> EC (Supplementary figure  
205 11B) revealed that malonic acid was sufficient to upregulate *Ucp-1*, *Cidea*, *Cd137*, *Cited1*,  
206 *Fgf21* and *Tmem26* gene expression in 3T3-L1 adipocytes (Figure 3A). A concentration of  
207 10mM malonic (Supplementary Figure 12) increased adiponectin secretion from 3T3-L1  
208 adipocytes (Figure 3B). Time-course experiments demonstrated malonic acid upregulated  
209 *Fgf21* gene expression first, followed by *Ucp-1* and *Cidea* gene expression (Figure 3C).

210

211 It has previously been shown that malonate, the ionised form of malonic acid, can increase  
212 reactive oxygen species (ROS) production<sup>31</sup>. We therefore asked if malonic acid-induced  
213 beiging is mediated by ROS. To answer this, we treated adipocytes with MitoQ, a  
214 mitochondrial-targeted antioxidant<sup>32</sup>, prior to malonic acid treatment. Removal of  
215 mitochondrial-generated ROS by MitoQ attenuated malonic acid-induced *Fgf21* gene  
216 upregulation (Figure 3D), demonstrating that malonic acid-induced upregulation of FGF21  
217 signalling is in part dependent on ROS.

218

219 FGF21 was previously reported as a paracrine/autocrine beiging mediator in WAT, enriched  
220 in murine rosiglitazone-stimulated beige adipocytes and norepinephrine-stimulated brown  
221 adipocytes<sup>33,34,35,36</sup>. An FGF21 receptor blocker (Figure 3E) diminished malonic acid induced  
222 upregulation of *Ucp-1* and *Cidea* in 3T3-L1 adipocytes, consistent with previous studies  
223 showing FGF21 regulates *Ucp-1*<sup>37,38</sup>.

224 To investigate the therapeutic potential of malonic acid as a beiging agent, we utilized various  
225 malonate prodrugs<sup>39</sup> (Supplementary figure 13). These malonate prodrugs accelerate  
226 malonate delivery *in vivo*<sup>39</sup>. The prodrug, di-tert-butyl malonate (DBM) induced an upregulation  
227 of *Cd137*, *Cited1*, *Fgf21* and *Ucp-1* gene expression in 3T3-L1 adipocytes (Figure 3F) and  
228 *UCP-1* and *CIDEA* gene expression in human primary adipocytes (Figure 3G), demonstrating  
229 a novel therapeutic strategy for inducing beiging in white adipocytes.

230

231 Although the action of malonic acid to inhibit succinate dehydrogenase (SDH) was established  
232 over 80 years ago<sup>40</sup>, our data demonstrate for the first time that, using an alternative  
233 concentration and exposure time, malonic acid leads to beiging of WAT. Mills *et al.*,<sup>41</sup> in a  
234 shivering thermogenesis model, suggested that elevated succinate led to browning of WAT in  
235 a SDH and ROS dependent fashion. In contrast to our findings, Mills *et al.*, suggested that  
236 malonic acid, by inhibiting SDH, blocked the effect of succinate. However, our data raise the  
237 possibility that malonic acid may act via an alternative pathway to induce adipocyte beiging in  
238 WAT in a ROS/FGF21 dependent fashion (Figure 3H).

239

## 240 **Summary**


241 In conclusion, our data reveal a hitherto unrecognised non-cell autonomous paracrine  
242 mechanism by which a reduction in EC IGF-1R stimulates beiging of WAT in mice challenged  
243 by a high-fat diet. Moreover, we present the novel finding that malonic acid, is released by the  
244 endothelium when IGF-1R levels are reduced and functions as a 'metabokine' leading to  
245 beiging of white adipocytes.

246

247

248 **Figures and legends**

**Figure 1**



249

250 **Figure 1 – Reduction in murine endothelial IGF-1R expression improves whole body**  
 251 **insulin sensitivity in the setting of over nutrition**

252 **A.** Schematic representation of the generation of tamoxifen-inducible endothelial cell specific  
 253 IGF-1R knock down mice (ECIGF-1R<sup>KD</sup>).

254 **B.** Schematic representation of experimental protocol.

255 **C.** Quantification of body weight from chow-fed control and ECIGF-1R<sup>KD</sup> mice and from 2-  
 256 week high fat fed (HFD) control and ECIGF-1R<sup>KD</sup> mice. (n=Chow 21&11, HFD 7 &8).

257 **D.** Quantification of wet organ weight from chow-fed control and ECIGF-1R<sup>KD</sup> mice and from  
 258 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n=Chow 2&3, HFD 26 &16).

259 **E.** Glucose tolerance over time for chow-fed control and ECIGF-1R<sup>KD</sup> mice and for 2-week  
 260 HFD control and ECIGF-1R<sup>KD</sup> mice (n=Chow 5&7, HFD 21&11).



261 **F.** Area under the curve (AUC) analysis for glucose tolerance test for chow fed control and  
262 ECIGF-1R<sup>KD</sup> mice and for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =Chow 5&7, HFD  
263 21&11).

264 **G.** Insulin tolerance test for chow-fed control and ECIGF-1R<sup>KD</sup> mice (n =4&3).

265 **H.** Insulin tolerance test for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =17&10).

266 **I.** The area under the curve analysis for insulin tolerance tests for chow-fed control and  
267 ECIGF-1R<sup>KD</sup> mice and from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =4,3,17&10).


268

269 Data shown as mean ± SEM, data points are individual mice. p<0.05 taken as statistically  
270 significant using student unpaired two tailed t-test and denoted as \*.

271

272

**Figure 2**



273

274 **Figure 2 – Reduction in murine endothelial IGF-1R expression prevents deleterious**  
 275 **remodelling of adipose tissue in the setting of over nutrition**

276 **A.** Energy expenditure in 2-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n =6&9).

277 **B.** Representative images of hematoxylin and eosin (H & E) stained white epididymal adipose  
 278 tissue from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 200μm).

279 **C.** Quantification of adipocyte size from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n  
 280 =9&17).

281 **D.** Quantification of white epididymal adipocyte size distribution from 2-week HFD control and  
 282 ECIGF-1R<sup>KD</sup> mice (n =9&17).

283 **E.** Representative images of isolectin B4 (Red) and LipidTox (Green) stained white  
 284 epididymal adipose tissue from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar  
 285 =100 μm).

286 **F.** Quantification of white epididymal adipose tissue vascularisation from 2-week HFD control  
 287 and ECIGF-1R<sup>KD</sup> mice (n =6&14).

288 **G.** Representative images of 2-week HFD control and ECIGF-1R<sup>KD</sup> white epididymal adipose  
 289 tissue explants (Scale bar = 200μm).

290 **H.** Quantification of white epididymal adipose tissue neovascularisation from 2-week HFD  
291 control and ECIGF-1R<sup>KD</sup> mice (n =5&5).

292 **I.** Quantification of plasma adiponectin levels from 2-week HFD control and ECIGF-1R<sup>KD</sup>  
293 mice (n =10&11).

294 **J.** Quantitation of white epididymal adipose gene expression from 2-week HFD control and  
295 ECIGF-1R<sup>KD</sup> mice (n =9-17).


296

297 Data shown as mean  $\pm$  SEM, data points are individual mice.  $p < 0.05$  taken as statistically  
298 significant using student unpaired two tailed t-test and denoted as \* (\*\* $p \leq 0.01$ ).

299

300

**Figure 3**



301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

**Figure 3 – Reduction in murine endothelial IGF-1R expression alters the endothelial secretome and reveals a role for malonic acid in modulating white adipose function**

**A.** Quantification of gene expression in 3T3-L1 adipocytes after 24hr 10mM malonic acid stimulation (n =4-7 per treatment).

**B.** Quantification of adiponectin secretion in 3T3-L1 adipocytes after 24hr 10mM malonic acid stimulation (n =3 per treatment group).

**C.** Quantification of gene expression in 3T3-L1 adipocytes after varying exposure times to 10mM malonic acid stimulation (n =4-7 per treatment group).

**D.** Quantification of *Fgf21* gene expression in 3T3-L1 adipocytes, after treatment with mitoQ and malonic acid 10mM for 24hrs (n =5 per treatment group).

**E.** Quantification of *Fgf21*, *Ucp-1* and *Cidea* gene expression in 3T3-L1 adipocytes after treatment with FGF1R blocker (PD17304) and malonic acid 10mM for 24hrs (n =3-5 per treatment group).

**F.** Quantification of gene expression in 3T3-L1 adipocytes after 24hr 10mM di-tert-butyl malonate (DBM) stimulation (n =3 per treatment group).

**G.** Quantification of gene expression in human primary adipocytes after 24hr 10mM di-tert-butyl malonate (DBM) stimulation (n =5 per treatment group).

319 **H.** Schematic diagram of the proposed mechanism of EC IGF-1R mediated white adipocyte  
320 beinging.

321


322 Data shown as mean  $\pm$  SEM, n is an individual experiment.  $p < 0.05$  taken statistically  
323 significant using student unpaired two tailed t-test or ANOVA and denoted as \* ( $p \leq 0.01$   
324 and is denoted as \*\*).

325

326

327

S Fig 1



328

329 **Supplementary figure 1 – Confirmation of IGF-1R reduction in murine model of**  
330 **endothelial specific IGF-1R knockdown**

- 331 **A.** Representative images of genotyping during the generation of ECIGF-1R<sup>KD</sup>.
- 332 **B.** Representative images of *en face* stained femoral arteries from tamoxifen-induced ECIGF-1R<sup>KD</sup> mice and control littermates confirming a switch from mT to mG with tamoxifen (Scale  
333 bar = 25 $\mu$ m).
- 334
- 335 **C.** Quantitation of primary murine endothelial cell expression of IGF-1R from 2-week HFD  
336 control and ECIGF-1R<sup>KD</sup> mice (n =16&8).
- 337 **D.** Quantitation of primary murine endothelial cell expression of insulin receptor (IR) from 2-  
338 week HFD control and ECIGF-1R<sup>KD</sup> mice (n =16&8).


339

340 Data shown as mean  $\pm$  SEM, data points are individual mice. p<0.05 taken as statistically  
341 significant using student unpaired two tailed t-test and denoted as \*.

342

343

## S Fig 2



344

345 **Supplementary figure 2 – No difference in metabolic plasma markers from mice with**  
346 **endothelial specific IGF-1R reduction in the setting of over nutrition**

347 **A.** Core body temperature of 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =15&8).

348 **B.** Fasting blood glucose levels of 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =13&21).

349 **C.** Fasting plasma insulin levels from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =6&8).

350 **D.** Fasting circulating plasma IGF-1 levels from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice  
351 (n =18&15).

352 **E.** Fasting plasma free fatty acids levels from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n  
353 =10&10).

354 **F.** Fasting plasma triglyceride levels from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n  
355 =10&10).


356 **G.** Fasting plasma leptin levels of 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n =11&5).

357

358 Data shown as mean ± SEM, data points are individual mice. p<0.05 taken as being  
359 statistically significant using student unpaired two tailed t-test and denoted as \*.

360

S fig 3



361

362 **Supplementary figure 3 – Characterisation of energy expenditure in mice with reduced**  
363 **endothelial IGF-1R expression after 2 weeks of high fat diet**

- 364 **A.** Oxygen consumption for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n= 6&9).  
365 **B.** Carbon dioxide production for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n= 6&9).  
366 **C.** Energy expenditure for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n= 6&9).  
367 **D.** Respiratory exchange ratio for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n= 6&9).  
368 **E.** Activity levels for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n= 6&9).  
369 **F.** Cumulative food consumption for 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n= 6&9).

370

371 The light/dark cycle for graphs A-E are shown as follows; Light in yellow and dark in blue.  
372 Data shown as mean ± SEM, p<0.05 taken as being statistically significant using student  
373 t-test and denoted as \*. Metabolic parameters were measured by indirect calorimetry,  
374 ANOVA testing was performed using mass as a co-variant (ANCOVA testing) using  
375 calrapp.org.


376

377

378



S Fig 4



379


380 **Supplementary figure 4 – Confirming endothelial cells in neovascularisation**

381 **A.** Staining of adipose tissue explants confirms sprouts are endothelial with positive isolectin  
382 B4 staining (green).

383

384

S fig 5



385

386 **Supplementary figure 5 – Deleterious remodelling of adipose tissue with increasing BMI**  
387 **and HbA1c.**

388 **A.** Representative images of hematoxylin and eosin (H & E)-stained white subcutaneous  
389 adipose tissue from patients with lower BMI and HbA1C and with higher BMI and HbA1c  
390 (Scale bar = 200µm).

391 **B.** Correlation between BMI and adipocyte area (n =17 patients).

392 **C.** Correlation between HbA1C and adipocyte area (n =17 patients).

393 **D.** Representative images of Ulex Europaeus (Red) and LipidTox (Green) stained white  
394 subcutaneous adipose tissue from patients with lower BMI and HbA1C and with higher  
395 BMI and HbA1c (Scale bar = 100µm).

396 **E.** Correlation between BMI and adipose vascularity (n= 21 patients).

397 **F.** Correlation between HbA1C and adipose vascularity (n= 21 patients).

398 **G.** Representative images of human white subcutaneous adipose tissue from patients with  
399 lower BMI and HbA1C and with higher BMI and HbA1c. (Scale bar = 100µm).

400 **H.** Correlation between BMI and adipose neovascularisation (n= 10 patients).

401 **I.** Correlation between HbA1C and adipose neovascularisation (n= 10 patients).


402

403 Data points are individual patients. Pearsons' correlation coefficients ( $r$ ) were calculated  
404 to assess the degree of relation between BMI and Hba1C and various fat markers.  $p < 0.05$   
405 taken as statistically significant.

406

407

S fig 6



408

409 **Supplementary figure 6 – Histological characterisation of mice with reduced endothelial**  
 410 **IGF-1R expression after 2 weeks of high fat diet**

411 **A.** Representative images of picro sirius red stained white epididymal adipose tissue from 2-  
 412 week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 200µm).

413 **B.** Quantification of white epididymal adipose collagen deposition from 2-week HFD control  
 414 and ECIGF-1R<sup>KD</sup> mice (n =7&9).

415 **C.** Representative images of Hematoxylin and eosin (H and E)-stained liver from 2-week HFD  
 416 control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 200µm).

417 **D.** Quantification of non-alcoholic fatty liver disease (NAFLD) from 2-week HFD control and  
 418 ECIGF-1R<sup>KD</sup> mice (n =5&3).

419 **E.** Representative images of H and E-stained brown interscapular adipose tissue from 2-  
 420 week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 100µm).

421 **F.** Quantification of lipid content of interscapular brown adipose tissue from 2-week HFD  
 422 control and ECIGF-1R<sup>KD</sup> mice (n =14&12).

423 **G.** Representative images of isolectin B4 (Red) and LipidTox (Green) stained brown  
 424 interscapular adipose tissue from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar =  
 425 100µm).

- 426 **H.** Quantification of vascularity in interscapular brown adipose tissue from 2-week HFD  
427 control and ECIGF-1R<sup>KD</sup> mice (n =6&14).
- 428 **I.** Representative images of isolectin B4 (Red) and LipidTox (Green) stained white  
429 subcutaneous adipose tissue from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar  
430 = 100µm).
- 431 **J.** Quantification of vascularity in white subcutaneous adipose tissue from 2-week HFD  
432 control and ECIGF-1R<sup>KD</sup> mice (n =6&4).
- 433 **K.** Representative images of isolectin B4 (Red) and LipidTox (Green) stained white  
434 perinephric adipose tissue from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar =  
435 100µm).
- 436 **L.** Quantification of vascularity in white perinephric adipose tissue from 2-week HFD control  
437 and ECIGF-1R<sup>KD</sup> mice (n =7&5).
- 438 **M.** Representative images of isolectin B4 (Red) and DAPI (Blue) stained liver from 2-week  
439 HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 50µm).
- 440 **N.** Quantification of liver vascularisation from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice (n  
441 =4&5).
- 442 **O.** Representative images of isolectin B4 (Red) and DAPI (Blue) stained muscle from 2-week  
443 HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 50µm).
- 444 **P.** Quantification of muscle vascularisation from 2-week HFD control and ECIGF-1R<sup>KD</sup> mice  
445 (n =7&8).


446

447 Data shown as mean ± SEM, Individual mice are shown as separate data points p<0.05  
448 taken as being statistically significant using a student unpaired two tailed t-test and  
449 denoted as \*.

450

451

S fig 7



452

453 **Supplementary figure 7 – Characterisation of adipose tissue from chow fed mice with**  
454 **reduced endothelial IGF-1R expression**

455 **A.** Representative images of isolectin B4 (Red) and LipidTox (Green) stained white  
456 epididymal adipose tissue from chow fed control and ECIGF-1R<sup>KD</sup> mice (Scale bar =  
457 100µm).

458 **B.** Quantification of vascularity in white epididymal adipose tissue from chow fed control and  
459 ECIGF-1R<sup>KD</sup> mice (n =3&5).

460 **C.** Quantification of *Ucp-1* and *Vegfa* gene expression in white epididymal adipose tissue  
461 from chow fed control and ECIGF-1R<sup>KD</sup> mice (n =4-11).


462

463 Data shown as mean ± SEM, Individual mice are shown as separate datapoints p<0.05  
464 taken as statistically significant using a student unpaired two tailed t-test and denoted as  
465 \*.

466

467

S fig 8



468

469 **Supplementary figure 8 – Metabolic characterisation of mice with reduced endothelial**  
 470 **IGF-1R expression after 8-weeks high fat diet.**

471 **A.** Representative western blot of primary murine endothelial cell expression of IGF-1R from  
 472 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice.

473 **B.** Quantitation of primary murine endothelial cell expression of IGF-1R from 8-week HFD  
 474 control and ECIGF-1R<sup>KD</sup> mice (n=2&2).

475 **C.** Body mass of 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n=20&10).

476 **D.** Wet organ weight of 8-week HFD control and ECIGF-1R<sup>KD</sup> mice (n=13&9).

477 **E.** Core body temperature of 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n=14&8).

478 **F.** Fasting blood glucose levels from 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n=7&7)

479 **G.** Glucose tolerance over time of 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n=13&7).

480 **H.** Area under the curve (AUC) analysis of glucose tolerance of 8-week HFD fed control and  
 481 ECIGF-1R<sup>KD</sup> mice (n=13&7).

482 **I.** Insulin tolerance over time of 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (N=18&11).

483 **J.** Area under the curve (AUC) analysis of insulin tolerance test of 8-week HFD fed control  
 484 and ECIGF-1R<sup>KD</sup> mice (n=18&11).

485 **K.** Fasting plasma insulin levels from 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n=6&4).

486 L. Fasting plasma IGF-1 levels from 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice  
487 (n=12&8).

488


489 Data shown as mean  $\pm$  SEM, individual mice are shown as separate datapoints p<0.05  
490 taken as being statistically significant using a student unpaired two tailed t-test and  
491 denoted as \*.

492

493



S fig 9



494

495 **Supplementary figure 9 – Histological characterisation of mice with reduced endothelial**  
496 **IGF-1R expression after 8-weeks of high fat diet.**

497 **A.** Representative images of Hematoxylin and eosin (H & E) stained white epididymal  
498 adipose tissue from 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 200µm).

499 **B.** Quantification of adipocyte size from 8-week HFD fed control and ECIGF-1R<sup>KD</sup> mice (n=  
500 12-18).

501 **C.** Representative images of H & E stained brown interscapular adipose tissue from 8-week  
502 HFD fed control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 200µm).

503 **D.** Quantification of lipid content of brown interscapular adipose tissue from 8-week HFD fed  
504 control and ECIGF-1R<sup>KD</sup> mice (n =18&13).

505 **E.** Representative images of isolectin B4 (Red) and LipidTox (Green) stained white  
506 epididymal adipose tissue from 8-week HFD control and ECIGF-1R<sup>KD</sup> mice (Scale bar =  
507 100µm).

508 **F.** Quantification of white epididymal adipose tissue vascularisation from 8-week HFD fed  
509 control and ECIGF-1R<sup>KD</sup> mice (n=6&6).

510 **G.** Quantitation of white epididymal adipose gene expression of *Ucp-1* and *Vegfa* from 8-  
511 week HFD fed control and ECIGF-1R<sup>KD</sup> mice. (n=12-15).

512 **H.** Representative images of picro sirius red stained white adipose tissue from 8-week HFD  
513 fed control and ECIGF-1R<sup>KD</sup> mice (Scale bar = 200 $\mu$ m).

514 **I.** Quantification of white epididymal adipose collagen deposition from 8-week HFD fed  
515 control and ECIGF-1R<sup>KD</sup> mice (n=14&10).

516 **J.** Representative images of H and E-stained liver from 8-week HFD fed control and ECIGF-  
517 1R<sup>KD</sup> mice (Scale bar = 200 $\mu$ m).

518 **K.** Quantification of non-alcoholic fatty liver disease (NAFLD) from 8-week HFD fed control  
519 and ECIGF-1R<sup>KD</sup> mice (n=20&11).


520

521 Data shown as mean  $\pm$  SEM, Individual mice are shown as separate datapoints p<0.05  
522 taken as being statistically significant using a student unpaired two tailed t-test and  
523 denoted as \*.

524

525

S fig 10



526

527 **Supplementary figure 10 – Reduction in murine endothelial IGF-1R expression alters**  
528 **the endothelial secretome and reveals a role for a small molecule in modulating**  
529 **adipocyte function**

530 **A.** Following induction with tamoxifen, cells of endothelial cell lineage in the ECIGF-1R<sup>KD</sup>  
531 fluoresce green using the mTmG system, with all other cells fluorescing red. All adipocytes  
532 from both genotypes appear red, confirming adipocytes are not from endothelial lineage.  
533 Quantitation of human primary adipocyte gene expression after 24hr treatment with  
534 conditioned media from primary murine endothelial cell isolated from 2-week HFD control  
535 and ECIGF-1R<sup>KD</sup> mice.


536 **B.** Quantitation of human primary adipocyte gene expression after treatment with boiled  
537 conditioned media from primary murine endothelial cells isolated from 2-week HFD fed  
538 control and ECIGF-1R<sup>KD</sup> mice (n=4&4).

539

540 Data shown as mean  $\pm$  SEM, individual mice are shown as separate datapoints p<0.05  
541 taken as being statistically significant using a student unpaired two tailed t-test and  
542 denoted as \*.

543

S fig 11



544

545 **Supplementary figure 11 – Mice with reduced endothelial IGF-1R expression after 2-**  
546 **weeks high fat diet have an altered endothelial small molecule secretome.**

547 **A.** Small molecule analysis of the aqueous and lipid fractions of conditioned media from  
548 primary murine endothelial cell from 2-week HFD fed control and ECIGF-1R<sup>KD</sup> mice  
549 (n=4&4 per genotype).

550 **B.** Quantitation of 3T3-L1 adipocyte gene expression of Ucp-1 after upregulated metabolite  
551 stimulation (n=3-5 per treatment group).

552 Data shown as mean ± SEM, n is an experimental replicates p<0.05 taken as statistically  
553 significant using student t-test and denoted as \*.


554

555

556

## S figure 12

A



557

### 558 **Supplementary figure 12 – Malonic acid dose response**

559 **A.** Quantification of gene expression of 3T3-L1 adipocytes treated with varying doses of  
560 malonic acid for 24hrs (n =5-14 per treatment group).


561

562 Data shown as mean  $\pm$  SEM, n is experimental replicates  $p < 0.05$  taken as being  
563 statistically significant using a one-way ANOVA and denoted as \* ( $p \leq 0.01$  and is denoted  
564 as \*\*).

565

566

S figure 13



567

568 **Supplementary figure 13 – Screening of malonic acid pro-drugs in 3T3-L1 adipocytes.**

569 **A.** Quantification of *Ucp-1* gene expression for 24hrs treatment with 10mM Diethyl malonate  
570 (DEM) (Chemical structure shown above). (n =3&3 per treatment group).

571 **B.** Quantification of *Ucp-1* gene expression for 24hrs treatment with 10mM Dipropyl  
572 Malonate (DPM) (Chemical structure shown above). (n =3&3 per treatment group).

573 **C.** Quantification of *Ucp-1* gene expression for 24hrs treatment with 10mM Dimethyl  
574 malonate (DMM) (Chemical structure shown above). (n =3&3 per treatment group).

575 **D.** Quantification of *Ucp-1* gene expression for 24hrs treatment with 10mM Dibenzyl  
576 Malonate (DBnM) (Chemical structure shown above). (n =3&3 per treatment group).

577 **E.** Quantification of *Ucp-1* gene expression for 24hrs treatment with 10mM meldrum's acid  
578 (MEL) (Chemical structure shown above). (n =3&3 per treatment group).

579

580 Data shown as mean  $\pm$  SEM, n is experimental replicates p<0.05 taken as statistically  
581 significant using an unpaired two sided student t-test and denoted as \*.

582 **References**

- 583 1. van Marken Lichtenbelt, W. D. et al. Cold-Activated Brown Adipose Tissue in Healthy  
584 Men. *N. Engl. J. Med.* 360, 1500–1508 (2009).
- 585 2. Virtanen, K. A. et al. Functional Brown Adipose Tissue in Healthy Adults. *N. Engl. J.*  
586 *Med.* 360, 1518–1525 (2009).
- 587 3. Cypess, A. M. et al. Identification and Importance of Brown Adipose Tissue in Adult  
588 Humans. *N. Engl. J. Med.* 360, 1509–1517 (2009).
- 589 4. Kajimura, S. & Saito, M. A New Era in Brown Adipose Tissue Biology: Molecular  
590 Control of Brown Fat Development and Energy Homeostasis. *Annu. Rev. Physiol.* 76, 225–  
591 249 (2014).
- 592 5. Wu, J., Cohen, P. & Spiegelman, B. M. Adaptive thermogenesis in adipocytes: Is  
593 beige the new brown? *Genes Dev.* 27, 234–250 (2013).
- 594 6. Yoneshiro, T. et al. Recruited brown adipose tissue as an antiobesity agent in  
595 humans. *J. Clin. Invest.* 123, 3404–3408 (2013).
- 596 7. Hanssen, M. J. W. et al. Short-term cold acclimation improves insulin sensitivity in  
597 patients with type 2 diabetes mellitus. *Nat. Med.* 21, 863–865 (2015).
- 598 8. Bartelt, A. et al. Brown adipose tissue activity controls triglyceride clearance. *Nat.*  
599 *Med.* 17, 200–205 (2011).
- 600 9. Stanford, K. I. et al. Brown adipose tissue regulates glucose homeostasis and insulin  
601 sensitivity. *J. Clin. Invest.* 123, 215–223 (2013).
- 602 10. Arch, J. R. S. Challenges in  $\beta$  3 -adrenoceptor agonist drug development. *Ther. Adv.*  
603 *Endocrinol. Metab.* 2, 59–64 (2011).
- 604 11. Kivelä, R. et al. Endothelial Cells Regulate Physiological Cardiomyocyte Growth via  
605 VEGFR2-Mediated Paracrine Signaling. *Circulation* 139, 2570–2584 (2019).
- 606 12. Noireaud, J. & Andriantsitohaina, R. Recent Insights in the Paracrine Modulation of  
607 Cardiomyocyte Contractility by Cardiac Endothelial Cells. *Biomed Res. Int.* 2014, 1–10  
608 (2014).
- 609 13. Wei, H. et al. Characterization of the polarized endothelial secretome. *FASEB J.* 33,  
610 12277–12287 (2019).
- 611 14. Haywood, N. J. et al. Endothelial IGF-1 receptor mediates crosstalk with the gut wall  
612 to regulate microbiota in obesity. *EMBO Rep.* 22, (2021).
- 613 15. Swinburn, B. A. et al. The global obesity pandemic: shaped by global drivers and  
614 local environments. *Lancet* 378, 804–814 (2011).
- 615 16. Mozaffarian, D., Hao, T., Rimm, E. B., Willett, W. C. & Hu, F. B. Changes in Diet and  
616 Lifestyle and Long-Term Weight Gain in Women and Men. *N. Engl. J. Med.* 364, 2392–2404  
617 (2011).
- 618 17. Schoeller, D. A. The energy balance equation: looking back and looking forward are  
619 two very different views. *Nutr. Rev.* 67, 249–254 (2009).
- 620 18. GBD. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N.*  
621 *Engl. J. Med.* 377, 13–27 (2017).
- 622 19. Hruby, A. et al. Determinants and Consequences of Obesity. *Am. J. Public Health*  
623 106, 1656–1662 (2016).
- 624 20. Pellegrinelli, V., Carobbio, S. & Vidal-Puig, A. Adipose tissue plasticity: how fat  
625 depots respond differently to pathophysiological cues. *Diabetologia* 59, 1075–1088 (2016).
- 626 21. Kajimura, S., Spiegelman, B. M. & Seale, P. Brown and Beige Fat: Physiological  
627 Roles beyond Heat Generation. *Cell Metab.* 22, 546–559 (2015).
- 628 22. Haywood, N. J., Slater, T. A., Matthews, C. J. & Wheatcroft, S. B. The insulin like  
629 growth factor and binding protein family: Novel therapeutic targets in obesity &  
630 diabetes. *Mol. Metab.* 19, (2019).
- 631 23. Imrie, H. et al. Vascular insulin-like growth factor-I resistance and diet-induced  
632 obesity. *Endocrinology* 150, 4575–4582 (2009).
- 633 24. Cubbon, R. M., Kearney, M. T. & Wheatcroft, S. B. Endothelial IGF-1 Receptor  
634 Signalling in Diabetes and Insulin Resistance. *Trends Endocrinol. Metab.* 27, 96–104 (2016).

- 635 25. Gogg, S., Nerstedt, A., Boren, J. & Smith, U. Human adipose tissue microvascular  
636 endothelial cells secrete PPAR $\gamma$  ligands and regulate adipose tissue lipid uptake. *JCI Insight*  
637 4, (2019).
- 638 26. Hammel, J. H. & Bellas, E. Endothelial cell crosstalk improves browning but hinders  
639 white adipocyte maturation in 3D engineered adipose tissue. *Integr. Biol.* 12, 81–89 (2020).
- 640 27. Crewe, C. et al. An Endothelial-to-Adipocyte Extracellular Vesicle Axis Governed by  
641 Metabolic State. *Cell* 175, 695–708.e13 (2018).
- 642 28. Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. *J. Clin.*  
643 *Endocrinol. Metab.* 89, 2548–2556 (2004).
- 644 29. Kusminski, C. M., Bickel, P. E. & Scherer, P. E. Targeting adipose tissue in the  
645 treatment of obesity-associated diabetes. *Nat. Rev. Drug Discov.* 15, 639–660 (2016).
- 646 30. Tran, K.-V. et al. The Vascular Endothelium of the Adipose Tissue Gives Rise to Both  
647 White and Brown Fat Cells. *Cell Metab.* 15, 222–229 (2012).
- 648 31. Fernandez-Gomez, F. J. et al. Malonate induces cell death via mitochondrial  
649 potential collapse and delayed swelling through an ROS-dependent pathway. *Br. J.*  
650 *Pharmacol.* 144, 528–537 (2005).
- 651 32. Kelso, G. F. et al. Selective Targeting of a Redox-active Ubiquinone to Mitochondria  
652 within Cells. *J. Biol. Chem.* 276, 4588–4596 (2001).
- 653 33. Sharp, L. Z. et al. Human BAT Possesses Molecular Signatures That Resemble  
654 Beige/Brite Cells. *PLoS One* 7, e49452 (2012).
- 655 34. Fisher, f. M. et al. FGF21 regulates PGC-1 and browning of white adipose tissues in  
656 adaptive thermogenesis. *Genes Dev.* 26, 271–281 (2012).
- 657 35. Hondares, E. et al. Thermogenic Activation Induces FGF21 Expression and Release  
658 in Brown Adipose Tissue. *J. Biol. Chem.* 286, 12983–12990 (2011).
- 659 36. Flippo, K. H. & Potthoff, M. J. Metabolic Messengers: FGF21. *Nat. Metab.* 3, 309–  
660 317 (2021).
- 661 37. Hill, C. M. et al. Low protein-induced increases in FGF21 drive UCP1-dependent  
662 metabolic but not thermoregulatory endpoints. *Sci. Rep.* 7, 8209 (2017).
- 663 38. Kwon, M. M., O'Dwyer, S. M., Baker, R. K., Covey, S. D. & Kieffer, T. J. FGF21-  
664 Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1. *Cell Rep.* 13,  
665 1521–1527 (2015).
- 666 39. Prag, H. A. et al. Ester Prodrugs of Malonate with Enhanced Intracellular Delivery  
667 Protect Against Cardiac Ischemia-Reperfusion Injury In Vivo. *Cardiovasc. Drugs Ther.*  
668 (2020) doi:10.1007/s10557-020-07033-6.
- 669 40. Baumann, C. & Stare, F. The effect of malonate on tissue respiration. *J Biol Chem*  
670 133, 183–191 (1940).
- 671 41. Mills, E. L. et al. Accumulation of succinate controls activation of adipose tissue  
672 thermogenesis. *Nature* 560, 102–106 (2018).
- 673 42. Dietrich, P., Dragatsis, I., Xuan, S., Zeitlin, S. & Efstratiadis, A. Conditional  
674 mutagenesis in mice with heat shock promoter-driven cre transgenes. *Mamm. Genome* 11,  
675 196–205 (2000).
- 676 43. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-  
677 fluorescent Cre reporter mouse. *genesis* 45, 593–605 (2007).
- 678 44. Stubbins, R. E., Holcomb, V. B., Hong, J. & Núñez, N. P. Estrogen modulates  
679 abdominal adiposity and protects female mice from obesity and impaired glucose tolerance.  
680 *Eur. J. Nutr.* 51, 861–870 (2012).
- 681 45. Griffin, C., Lanzetta, N., Eter, L. & Singer, K. Sexually dimorphic myeloid  
682 inflammatory and metabolic responses to diet-induced obesity. *Am. J. Physiol. Integr. Comp.*  
683 *Physiol.* 311, R211–R216 (2016).
- 684 46. Haywood, N. J. et al. Insulin-Like Growth Factor Binding Protein 1 Could Improve  
685 Glucose Regulation and Insulin Sensitivity Through Its RGD Domain. *Diabetes* 66, 287–299  
686 (2017).
- 687 47. Abbas, A. et al. The insulin-like growth factor-1 receptor is a negative regulator of  
688 nitric oxide bioavailability and insulin sensitivity in the endothelium. *Diabetes* 60, 2169–2178  
689 (2011).



- 690 48. Watt, N. T. et al. Endothelial SHIP2 Suppresses Nox2 NADPH Oxidase–Dependent  
691 Vascular Oxidative Stress, Endothelial Dysfunction, and Systemic Insulin Resistance.  
692 *Diabetes* 66, 2808–2821 (2017).
- 693 49. Whitehead, A. et al. Brown and beige adipose tissue regulate systemic metabolism  
694 through a metabolite interorgan signaling axis. *Nat. Commun.* 12, 1905 (2021).
- 695 50. Roberts, L. D. et al.  $\beta$ -Aminoisobutyric Acid Induces Browning of White Fat and  
696 Hepatic  $\beta$ -oxidation and is Inversely Correlated with Cardiometabolic Risk Factors. *Cell*  
697 *Metab.* 19, 96–108 (2014).
- 698 51. Liang, W., Menke, A. L., Driessen, A., Koek, G. H. & Lindeman, J. H. Establishment  
699 of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver  
700 Pathology. *PLoS One* 9, 1–17 (2014).
- 701 52. Greenway, F. L. et al. An Assay to Measure Angiogenesis in Human Fat Tissue.  
702 *Obes. Surg.* 17, 510–515 (2007).
- 703 53. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF  
704 receptor tyrosine kinase domain. *EMBO J.* 17, 5896–5904 (1998).
- 705

## 706 **Methods**

### 707 *In vivo animal studies*

708 Mice with tamoxifen-inducible endothelial cell specific knockdown of the IGF-1R receptor  
709 (ECIGF-1R<sup>KD</sup>) and their *lox/lox* control littermates, were bred in house from founder animals  
710 (VE-Cre #MGI 3848984, *Igf1r*<sup>(lox)</sup> #MGI:J:60711<sup>42</sup>, mTmG #MGI:J:124702<sup>43</sup>. Experiments were  
711 carried out under the authority of UK Home Office Licence P144DD0D6. Mice were group  
712 housed in cages of up to five animals. Only male mice were used for experimental procedures  
713 to prevent variability associated with the estrous cycle on adiposity and metabolic readouts  
714 <sup>44,45</sup>. Cages were maintained in humidity- and temperature-controlled conditions (humidity  
715 55% at 22°C) with a 12hr light-dark cycle. Genotyping was carried out by Transnetyx  
716 commercial genotyping using ear biopsies'. At 5 weeks old, mice were injected with tamoxifen  
717 (T5648 Sigma, dissolved in, Corn Oil – also from Sigma, C8267) (1mg/day intra-peritoneal for  
718 5 consecutive days). To induce obesity, 8 week old male mice received high fat diet *ad libitum*  
719 for either 2 weeks or 8 weeks (60% of energy from fat) (F1850, Bioserve) with the following  
720 composition: protein 20.5%, fat 36% and carbohydrate 36.2% (5.51 kcal/g).

721

### 722 *Insulin and glucose tolerance testing*

723 Mice were fasted overnight prior to glucose tolerance tests or for 2hr prior to insulin tolerance  
724 tests. Blood glucose was measured using a handheld Glucose Meter (Accu-Chek Aviva). An  
725 intra-peritoneal injection of glucose (1mg/g) or recombinant human insulin (Actrapid; Novo  
726 Nordisk) (0.75IU/kg) was given and glucose concentration measured at 30min intervals for  
727 2hrs from the point of glucose/insulin administration. Mice were not restrained between  
728 measurements<sup>46</sup>. Data were analysed using GraphPad Prism Area under the curve (AUC)  
729 calculations.

730

731 *Genotyping of endothelial cell specific knockdown of the IGF-1R receptor (ECIGF-1R<sup>KD</sup>) and*  
732 *their lox/lox control littermates*

733 VE-cre reaction mix; 0.5µl 10µM Forward Primer: 5'-  
734 GCATTACCGGTTCGATGCAACGAGTGATGAG -3' 0.5µl 10µM Reverse Primer: 5'-  
735 GAGTGAACGAACCTGGTCGAAATCAGTGCG -3' 10µl x2 Bio mix red PCR Master Mix, 13µl  
736 water and 1µl extracted DNA. PCR cycle as follows; Initial denaturation 95°C for 1 min,  
737 denaturation 95°C for 15 sec, annealing 51°C for 30 sec, extension 72°C for 1 min and final  
738 extension 72°C for 6 min. Denaturation, annealing and extension repeated for 35 cycles. PCR  
739 products were then run on a 1.5% agarose gel for 1 hr at 110 V, with a 100 bp ladder. Expected  
740 product sizes are Cre Positive – 408 bp.

741

742 IGF-1R lox reaction mix; 1 µl 10µM Forward Primer1: 5'-CTTCCCAGCTTGCTACTCTAG G -  
743 3' 1 µl 10µM Forward Primer2: 5'-TGAGACGTAGCGAGATTGCTGTA -3' 1µl 10µM Reverse  
744 Primer: 5'-CAGGCTTGCAATGAGACATGGG -3' 10µl x2 Bio mix red PCR MasterMix, 11 µl  
745 water and 1µl extracted DNA. PCR cycle as follows; Initial denaturation 94°C for 4 min,  
746 denaturation 94°C for 45 sec, annealing 61°C for 45 sec, extension 72°C for 1 min and final  
747 extension 72°C for 5 min. Denaturation, annealing and extension repeated for 35 cycles. PCR  
748 products were then run on a 1.5% agarose gel for 1 hr at 110 V, with a 100 bp ladder. Expected  
749 products sizes are; Wild type – 120 bp, Homozygous – 220 bp and Heterozygous – 120 & 220  
750 bp.

751

752 mTmG reaction mix; 0.5µl 10µM Common Primer: 5'- CTCTGCTGCCTCCTGGCTTCT-3'  
753 0.5µl 10µM Wild type Reverse Primer: 5'-CGAGGCGGATCACAAGCAATA-3' 0.5µl 10µM  
754 Mutant Reverse Primer: 5'-TCAATGGGCGGGGTCGTT-3' 10µl x2 Bio mix red PCR Master  
755 Mix, 12.5µl water and 1µl extracted DNA. PCR cycle as follows; Initial denaturation 94°C for  
756 2 min, denaturation 94°C for 30 sec, annealing 62°C for 30 sec, extension 72°C for 30 sec  
757 and final extension 72°C for 10 min. Denaturation, annealing and extension repeated for 35  
758 cycles. PCR products were then run on a 1.5% agarose gel for 1 hr at 110 V, with a 100 bp  
759 ladder. Expected product sizes are; Wild type - 330 bp, Homozygous - 250 bp, and  
760 Heterozygous - 250 & 350 bp.

761

762 *Confirmation of tamoxifen induction of mT to mG*

763 Founder mTmG mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). In  
764 the absence of Cre recombinase, mTmG mice constitutively express mTdTomoato, a non-  
765 oligomerizing DsRed variant. After tamoxifen induction and therefore following exposure to  
766 Cre recombinase and excision of the mTdTomoato expression cassette, the rearranged mTmG  
767 transgene converts to the expression of mGFP (green fluorescent protein). Both mTdTomoato

768 and mGFP are membrane-targeted, allowing for delineation of single cells using fluorescence  
769 microscopy. Mice were perfuse-fixed with 4% paraformaldehyde (PFA). Femoral arteries were  
770 excised, permeabilised (0.1% TritonX-100 in PBS) and blocked (Serum free protein block,  
771 DAKO), before overnight incubation with a rabbit polyclonal antibody to mouse CD31  
772 (ab28364, Abcam) followed by overnight incubation with a goat polyclonal anti-rabbit  
773 conjugated to Chromeo642 (ab60319, Abcam, UK). Arteries were then mounted *en face* on  
774 slides using DAPI (DAPI-Fluoromount-G, Southern Biotech) to define nuclei. Confocal  
775 microscopy (LSM 700, Zeiss, UK) was used to define CD31, mGFP and mTdTtomato  
776 fluorescence.

777

#### 778 *Primary endothelial cell isolation and culture*

779 Primary endothelial cells (PECs) were isolated from lungs, as previously reported<sup>47,48</sup>. Briefly,  
780 lungs were harvested, washed, finely minced, and digested in Hanks' balanced salt solution  
781 containing 0.18 units/mL collagenase (10 mg/mL; Roche) for 45min at 37°C. The digested  
782 tissue was filtered through a 70- $\mu$ m cell strainer and centrifuged at 1,000 RPM for 10 min. The  
783 cell pellet was washed with PBS/0.5% BSA, centrifuged, re-suspended in 1mL PBS/0.5%  
784 BSA, and incubated with  $1 \times 10^6$  CD146 antibody-coated beads (Miltenyi Biotech, 130-092-  
785 007) at 4°C for 30min. Bead-bound PEC were separated from non-bead-bound cells using a  
786 magnet. Cells were re-suspended in 2ml supplemented endothelial growth medium-MV2  
787 (PromoCell) and seeded on a 6 well fibronectin coated plates. Cells were cultured at 37°C in  
788 5% CO<sub>2</sub> with twice-weekly media changes until confluent.

789

#### 790 *Quantification of protein expression*

791 Cells were lysed or tissue mechanically homogenised in lysis buffer (Extraction buffer,  
792 FNN0011) and protein content was quantified by a BCA assay (Sigma-Aldrich, St. Louis, MO).  
793 Twenty micrograms of protein were resolved on a 4-12% Bis-Tris gel (Bio-Rad, Hertfordshire,  
794 UK) and transferred to nitrocellulose membranes. Membranes were probed with antibodies  
795 diluted in 5% BSA (IGF-1R and IR, Cell signalling #9750 and #3025 respectively), before  
796 incubation with appropriate secondary horseradish peroxidase-conjugated antibody. Blots  
797 were visualised with Immobilon Western Chemiluminescence HRP Substrate (Merck Millipore,  
798 Hertfordshire, UK) and imaged with Syngene chemiluminescence imaging system (SynGene,  
799 Cambridge, UK). Densitometry was performed in ImageJ.

800

#### 801 *Plasma samples*

802 Fasting plasma samples were collected from the lateral saphenous vein (EDTA collection  
803 tubes Sarstedt 16.444) and spun at 10,000 RPM for 10min in a bench top centrifuge. Fasting  
804 plasma insulin (90080, CrystalChem), IGF-I (MG100, R and D systems), leptin (EZML-82K,

805 Merk-Millipore), adiponectin (EZMADP-60K, Merk-Millipore) triglycerides (Abcam Ab65336)  
806 and free fatty acids (Abcam, ab65341) were measured as per manufactures instructions.

807

#### 808 *Metabolic phenotyping*

809 Metabolic parameters were measured by indirect calorimetry using Comprehensive Lab  
810 Animal Monitoring Systems (CLAMS)(Columbus Instruments). In brief, mice were individually  
811 housed for 5 days and measurement of their oxygen consumption, carbon dioxide production,  
812 food intake, and locomotor activity were continuously recorded<sup>49</sup>. For each mouse, a full 24  
813 hour period, taking into account sleep and wake cycles, was analysed after an acclimatisation  
814 period<sup>50</sup>. Core body temperature was measured using a rectal temperature probe (Vevo2100  
815 (Visualsonics, FujFilm) with an Indus rectal temperature probe).

816

#### 817 *Murine tissue samples*

818 After either 2 or 8 weeks of high fat feeding, all mice were sacrificed using terminal anaesthesia  
819 and organ weights measured using a standard laboratory balance.

820

#### 821 *Quantification of gene expression*

822 RNA was isolated from tissue and cells samples (NEB, T2010S). The concentration of RNA  
823 in each sample (ng/ul) was measured using a Nanodrop. cDNA was reverse transcribed from  
824 the RNA samples (NEB, E3010L). Quantitative PCR (qPCR) was performed using a Roche  
825 LightCycler 480 Instrument II, using SYBR Green PCR Master Mix (Bio-Rad, 1725120) and  
826 relevant primers (Table 1). The 'cycles to threshold' (cT) was measured for each well, the  
827 average of triplicate readings for each sample taken, normalised to GAPDH, and finally the  
828 differential expression of each gene was calculated for each sample.

829

#### 830 *Histological assessment of adipocyte size, fibrous tissue and non-alcoholic fatty liver disease*

831 Samples for histology were fixed in 4% PFA for at least 24hrs and then processed into paraffin  
832 blocks. 5µm sections were taken, slides were stained with haematoxylin and eosin to assess  
833 gross morphology or Picro-sirius red for collagen deposition. Slides were imaged using an  
834 Olympus BX41 microscope at 10x and 20x magnification. For assessment of adipocyte size,  
835 three separate fields of view for each sample were assessed. For each one, the average was  
836 taken of 20 randomly selected independent cells measured using ImageJ. For collagen  
837 deposition, the percentage of the sample staining positive for collagen was measured using  
838 thresholding in ImageJ, and again was taken as the average in at least three independent  
839 areas of the sample. For assessment of non-alcoholic fatty liver disease (NAFLD) in sections  
840 of murine liver, a validated rodent NAFLD scoring system was used<sup>51</sup>, which takes into account  
841 micro and macro-steatosis, inflammation and hypertrophy. Each sample was assessed by at

842 least two blinded independent verifiers (NH, KB or NW), and the average score per sample  
843 taken.

844

#### 845 *Quantification of tissue vascularity*

846 Adipose tissue was fixed in 1% paraformaldehyde (PFA), and allowed to fix for 2hrs at room  
847 temperature; samples were transferred into phosphate buffered saline (PBS) for longer  
848 storage. Samples were incubated overnight with lectin from *Ulex europaeus* Alexa Fluor 594  
849 (73873, Sigma) (For human samples) or Isolectin B4 Alexa Fluor 647 (I32450, Thermo Fisher  
850 Scientific) (for murine samples), diluted 1:100 in 5% BSA in PBS at 4°C. After washing with  
851 PBS, they were incubated with HCS LipidTOX (H34475, Thermo Fisher Scientific) diluted  
852 1:200 in PBS for 20mins at room temperature. Whole tissue sections were then mounted onto  
853 slides beneath cover slips using a silicone spacer (Grace bio-labs, 664113), with Prolong Gold  
854 (P36930, Thermo Fisher Scientific). Vascular density (the proportion of each image stained  
855 with lectin) was measured using thresholding in ImageJ. Green staining is a composite of GFP  
856 and Lipidtox in mice samples, green is not quantified.

857

858 Organs (Muscle and liver) were harvested under terminal anaesthesia and fixed in 4% PFA  
859 for 1hr at room temperature. Organs were then embedded in Optimal Cutting Temperature  
860 compound (OCT) (Cellpath, KMA-0100-00A) and stored at -80 until sectioned. 10µM sections  
861 were taken using a Leica CM3050 S Research Cryostat. Slides were blocked and  
862 permeabilised in PBS + 0.25% Triton-X100 + 1% BSA + for one hour, then stained with  
863 Isolectin B4-Alexa Fluor-488 (Invitrogen I21411) at 1/100 in PBS + 0.25% Triton + 1% BSA  
864 for 1hr. Slides were washed three times in PBS and mounted with a coverslip using Prolong  
865 Gold with DAPI (P36931, ThermoFisher). Slides were then imaged using laser scanning  
866 confocal microscopy (LSM880, Zeiss), with 8 areas of each sample imaged. Vascular density  
867 (the proportion of each image stained with IB4) was measured using thresholding in ImageJ.

868

#### 869 *Assessment of neovascularisation in white adipose tissue*

870 Angiogenesis assays from adipose tissue were performed using a modified technique based  
871 on previously published methods<sup>52</sup>. In sterile conditions, any surface blood vessels were  
872 dissected from the adipose tissue sample, before it was cut into pieces no bigger than 1mm<sup>3</sup>.  
873 For each sample, at least 20 sections were embedded into a fibrin matrix. The fibrin matrix  
874 was achieved by combining 12.5ul of 50 U/ml thrombin (Sigma-Aldrich T-3399) with 500ul of  
875 a mix containing 4 U/ml aprotinin (Sigma-Aldrich A-1153) and 2 mg/ml fibrinogen type 1  
876 (Sigma-Aldrich F-8630), and adding a piece of adipose tissue into the well before the matrix  
877 had set. The plates were then incubated at room temperature for 20 minutes, and then at 37°C  
878 for a further 20 minutes to ensure that the matrix had fully formed around the piece of adipose

879 tissue. One millilitre of media was then carefully pipetted onto the top of each well, and plates  
880 were cultured at 37°C, 5% CO<sub>2</sub> for up to 7 days. The media was discarded and replaced every  
881 other day throughout the culture period. Each day, the samples were imaged at 4x  
882 magnification on Olympus florescent microscope CKX41 and number of endothelial sprouts  
883 coming from each piece of fat was counted. For each sample, the average number of sprouts  
884 per section was calculated, as well as the number of sections which had sprouted.

885

#### 886 *Human adipose tissue explants*

887 Human subcutaneous white adipose tissue was obtained after informed consent from patients  
888 undergoing pacemaker implantation at Leeds Teaching Hospitals NHS Trust, Leeds, United  
889 Kingdom, after ethical approval (REC: 11/YH/0291). Adipose tissue was removed from the  
890 area between the skin and pectoralis major, under local anaesthetic (1% lidocaine). Patient  
891 demographics are provided in table 2.

892

#### 893 *Conditioning media*

894 When PECS reached confluency, supplemented growth media was removed and replaced  
895 with basal endothelial growth medium–MV2 (Promocell) for 24hrs. Conditioned media was  
896 then removed and used in further experiments as described.

897

#### 898 *Quantification of browning in human adipocytes*

899 Human primary adipocytes (PromoCell, C-12730) were seeded (10,000 cells/cm<sup>2</sup>) in 24 well  
900 plates (Costar, Corning, NY, USA) and grown until confluence (37°C, 5% CO<sub>2</sub>) in PromoCell  
901 Preadipocyte Growth Medium (C-27410, 0.05 mL/mL fetal calf serum, 0.004 mL/mL  
902 endothelial cell growth supplement, 10 ng/mL epidermal growth factor, 1 µg/mL  
903 hydrocortisone, 90 µg/mL heparin) as previously described<sup>49</sup>. To differentiate confluent pre-  
904 adipocytes, growth medium was replaced by PromoCell Adipocyte Differentiation Medium (C-  
905 27436, 8 µg/mL d-Biotin, 0.5 µg/mL insulin, 400 ng/mL dexamethasone, 44 µg/mL IBMX, 9  
906 ng/mL L-thyroxine, 3 µg/ml ciglitazone) for 48 hours (day 0). Differentiation medium was  
907 subsequently replaced (day 2) with PromoCell Adipocyte Nutrition Medium (C-27438, 0.03  
908 mL/mL fetal calf serum, 8 µg/mL d-Biotin, 0.5 µg/mL insulin, 400 ng/mL dexamethasone) for  
909 the remainder of the differentiation period (up to day 14). All Cell medium was supplemented  
910 with 1% penicillin-streptomycin (10,000 units/mL penicillin, 10 mg/mL streptomycin).  
911 Conditioned media was then added to the differentiated human adipocytes for 24hrs before  
912 the cells were lysed and RNA extracted for gene expression analysis. To determine if browning  
913 was caused by a protein or small molecule, parallel experiments were conducted whereby the  
914 conditioned media was boiled for 5mins at 95°C, to denature any proteins, before being added  
915 to the human adipocytes.

916

917 *Metabolite & pro-drug screening*

918 Mouse 3T3-L1 preadipocytes were cultured in 10% (v/v) CS/DMEM containing 4.5 g/l glucose  
919 and 1mM Sodium Pyruvate and supplemented with 1XAntibiotic Antimycotic Solution and  
920 incubated at 37°C in 5% CO<sub>2</sub> for two days upon splitting. Two days after splitting, the media  
921 was replaced by 10% (v/v) FBS/DMEM to grow the cells to confluency. After two days of post-  
922 confluency (equivalence of day 0), adipocyte differentiation was initiated with MDI induction  
923 media (10% FBS/DMEM, 0.5mM IBMX, 1µM dexamethasone and 1µg/mL insulin). On day 2,  
924 the MDI induction media was replaced by insulin media (10% FBS/DMEM supplemented with  
925 1µg/mL insulin). From day 4 onwards, the media was replaced by 10% FBS/DMEM every two  
926 days. Full differentiation was achieved between day 7 and day 10. Mature adipocytes were  
927 subjected to metabolite stimulation. Metabolites, Malonic acid<sup>31</sup> or pro-drugs (Table 3) and  
928 their solvents, DPBS or DMSO, were applied for 24 hours at 37°C in 5% CO<sub>2</sub>.

929

930 *Adiponectin secretion*

931 After stimulation of the mature 3T3-L1 adipocytes, the conditioned media was collected and  
932 centrifuged at 13,400 rpm for 10 min at 4°C to pellet cell debris. The supernatants were then  
933 used to quantify the level of adiponectin using Mouse Adiponectin ELISA kit (Merck Millipore  
934 #EZMADP-60K) according to the manufacturer's instructions.

935

936 *FGFR1 blocker*

937 20nM PD173074 (Apexbio #A8253) was applied an hour prior to 24-hour malonic acid  
938 treatment<sup>53</sup>.

939

940 *Mitochondria-targeted antioxidant*

941 100nM Mitoquinone (MitoQ; MedChemExpress LLC #HY-100116A) was applied 30min prior  
942 to 24-hour malonic acid treatment<sup>41</sup>.

943

944 *Separation of conditioned media into aqueous and lipid fractions*

945 600µl of 2:1 methanol:chloroform was added to 1 ml of conditioned media, followed by 200 µl  
946 of water and an additional 200µl of chloroform, vortexed and then centrifuged at 13.1g for  
947 20mins. The top layer (aqueous layer containing the aqueous metabolites) was pipetted off  
948 and placed into the evacuation centrifuge at 40°C for 6 hours. The protein disc (middle layer)  
949 was discarded and the final bottom layer (containing lipid metabolites) was transferred into a  
950 clean Eppendorf and left overnight in a fume hood at room temperature until all chloroform  
951 had evaporated. Both the lipid and aqueous metabolites were stored at -80°C.

952

953 *Aqueous Sample Preparation*

954 Samples were reconstituted in 1 ml sample resuspension buffer (95% acetonitrile and 5 %  
955 mobile phase A). Mobile phase A = 95% water, 5% acetonitrile, 20mM ammonium acetate  
956 and 20mM ammonium hydroxide, pH = 9. Samples were vortex mixed and the extracted  
957 metabolites were transferred to a 2 mL glass vial.

958

959 *Liquid Chromatography*

960 A SCIEX ExionLC™ AD HPLC system with a Luna 3 μm NH<sub>2</sub> 100 Å, 150 x 4.6 mm column  
961 (Phenomenex) was used. Mobile phase A = 95% water, 5% acetonitrile, 20mM ammonium  
962 acetate and 20mM ammonium hydroxide, pH = 9; Mobile phase B = 95% acetonitrile and 5%  
963 mobile phase A and 20 mM ammonium hydroxide. The flow rate was set at 350 μL/min. The  
964 wash solvent for the autosampler was 20/20/60 methanol/acetonitrile/isopropanol. The  
965 injection volume was 2 μL, and the column was kept at 40°C. The gradient method was 100%  
966 B for 2 minutes, then to 85% B for 3 minutes, then to 30% for 10min, then to 2% B for 5min,  
967 then 100% for 10min.

968

969 *Mass Spectrometry*

970 A SCIEX QTRAP® 6500+ with IonDrive Turbo V source was used. MS source parameters  
971 are Curtain Gas was 30 for both (+) and (-). Collision Gas was high for both (+) and (-),  
972 ionspray voltage was 5500 for (+) and -4500 for (-). Temperature was 500 for both (+) and (-  
973 ), Ion source gas 1 was 35 for both (+) and (-), ion source gas was 45 for both (+) and (-),  
974 delustering potential was 93 for (+) and -93 for (-), entrance potential was 10 for (+) and -10  
975 for (-) and collision cell exit potential was 10 for (+) and -10 for (-).

976

977 *Quantification and statistical analysis*

978 Priori sample size calculations for animal experiments were performed using our published  
979 pilot data using the online software package from Vanderbilt University for multiple types of  
980 power analysis (<https://biostat.app.vumc.org/wiki/Main/PowerSampleSize>). All data are  
981 shown as mean ± SEM. Individual mice or replicates are shown as individual data points. All  
982 image analysis was performed in ImageJ. Pearsons' correlation coefficients (*r*) were  
983 calculated to assess the link and the degree of relation between BMI and HbA1C and various  
984 fat markers. Student 2-tailed unpaired t-test or one-way ANOVA (where appropriate) were  
985 used for statistical analyses and were performed with GraphPad Prism software version 7. \*  
986 denotes P ≤0.05 and \*\* P ≤0.01. Exact details can be found in figure legends.

987

988 *Data availability*



989 The data that support the findings of this study are available from the corresponding author  
990 upon reasonable request.

991

## 992 **Method references**

- 993 42. Dietrich, P., Dragatsis, I., Xuan, S., Zeitlin, S. & Efstratiadis, A. Conditional  
994 mutagenesis in mice with heat shock promoter-driven cre transgenes. *Mamm. Genome* 11,  
995 196–205 (2000).
- 996 43. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-  
997 fluorescent Cre reporter mouse. *genesis* 45, 593–605 (2007).
- 998 44. Stubbins, R. E., Holcomb, V. B., Hong, J. & Núñez, N. P. Estrogen modulates  
999 abdominal adiposity and protects female mice from obesity and impaired glucose tolerance.  
1000 *Eur. J. Nutr.* 51, 861–870 (2012).
- 1001 45. Griffin, C., Lanzetta, N., Eter, L. & Singer, K. Sexually dimorphic myeloid  
1002 inflammatory and metabolic responses to diet-induced obesity. *Am. J. Physiol. Integr. Comp.*  
1003 *Physiol.* 311, R211–R216 (2016).
- 1004 46. Haywood, N. J. et al. Insulin-Like Growth Factor Binding Protein 1 Could Improve  
1005 Glucose Regulation and Insulin Sensitivity Through Its RGD Domain. *Diabetes* 66, 287–299  
1006 (2017).
- 1007 47. Abbas, A. et al. The insulin-like growth factor-1 receptor is a negative regulator of  
1008 nitric oxide bioavailability and insulin sensitivity in the endothelium. *Diabetes* 60, 2169–2178  
1009 (2011).
- 1010 48. Watt, N. T. et al. Endothelial SHIP2 Suppresses Nox2 NADPH Oxidase–Dependent  
1011 Vascular Oxidative Stress, Endothelial Dysfunction, and Systemic Insulin Resistance.  
1012 *Diabetes* 66, 2808–2821 (2017).
- 1013 49. Whitehead, A. et al. Brown and beige adipose tissue regulate systemic metabolism  
1014 through a metabolite interorgan signaling axis. *Nat. Commun.* 12, 1905 (2021).
- 1015 50. Roberts, L. D. et al.  $\beta$ -Aminoisobutyric Acid Induces Browning of White Fat and  
1016 Hepatic  $\beta$ -oxidation and is Inversely Correlated with Cardiometabolic Risk Factors. *Cell*  
1017 *Metab.* 19, 96–108 (2014).
- 1018 51. Liang, W., Menke, A. L., Driessen, A., Koek, G. H. & Lindeman, J. H. Establishment  
1019 of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver  
1020 Pathology. *PLoS One* 9, 1–17 (2014).
- 1021 52. Greenway, F. L. et al. An Assay to Measure Angiogenesis in Human Fat Tissue.  
1022 *Obes. Surg.* 17, 510–515 (2007).
- 1023 53. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF  
1024 receptor tyrosine kinase domain. *EMBO J.* 17, 5896–5904 (1998)

1025

<b>Gene</b>	<b>Bio-rad Assay code</b>
<i>Adipoq</i>	qMmuCED0045486
<i>Cidea</i>	qMmuCID0007140
<i>Cd137</i>	qMmuCED0047964
<i>Cited1</i>	qMmuCED0037644
<i>Cox8b</i>	qMmuCID0020689
<i>Cycs</i>	qMmuCED0001027
<i>Fgf21</i>	qMmuCED0025797
<i>Gapdh</i>	qMmuCED0027497
<i>Lep</i>	qMmuCID0040177
<i>Ppargc1a</i>	qMmuCID0006032
<i>Ppara</i>	qMmuCED0046526
<i>Ppar<math>\gamma</math></i>	qMmuCID0018821
<i>Tbx1</i>	qMmuCID0011851

<i>Tmem26</i>	qMmuCED0061015
<i>Ucp1</i>	qMmuCED0047500
<i>Vegfa</i>	qMmuCED0040260
<i>CD137</i>	qHsaCID0020895
<i>CIDEA</i>	qHsaCED0003559
<i>CYCS</i>	qHsaCED0046874
<i>FGF21</i>	qHsaCIP0032896
<i>GAPDH</i>	qHsaCED0038674
<i>PPARGC1α</i>	qHsaCID0006418
<i>TMEM26</i>	qHsaCID0009380
<i>UCP-1</i>	qHsaCED0043275

**Table 1: Primers for qPCR**

1026

1027

	Mean ( $\pm$ SEM)
Male	28
Female	15
Diabetes	12
Age (Years)	68 (1.98)
Weight (Kg)	86.23 (3.12)
Height (m)	1.69 (0.013)
BMI (Kg/m <sup>2</sup> )	29.65 (0.79)
HbA1c (mmol/mol)	46.75(2.469)

**Table 2. Patient characteristics**

1028

1029

1030

Metabolite/prodrug	Conc	Manufacturer	Cat #
2'-deoxycytidine triphosphate (dCTP)	10 mM	Thermo Scientific	R0151
2'-deoxyuridinemonophosphate	2 mM	Santa Cruz	sc-214058
Arginine	2 mM	Alfa Aesar	11498850
Citric acid specific	2 mM	SIGMA-ALDRICH	C0759
Cytidine monophosphate (CMP)	2 mM	Fluorochem	47062
Folic acid	11.3 $\mu$ M	SIGMA-ALDRICH	F7876
Glucosamine 6P (G6P)	2 mM	Santa Cruz	sc-214809
Glucuronic acid	10 ng/ml	SIGMA-ALDRICH	G5269
Glutamine	2 mM	Thermo Fisher	25030032
Guanosine diphosphate (GDP)	10 $\mu$ M	MedChemExpress	HY113066A
Guanosine-3'5'-cyclic monophosphate	200 $\mu$ M	SIGMA-ALDRICH	G7504
Inosine	100 $\mu$ M	Alfa Aesar	A14459.06
Inosine monophosphate (IMP)	1.25 mM	SIGMA-ALDRICH	57510
Leucine	2 mM	G BIOSCIENCES	RC-064
Maleic acid	8 mM	Acros Organics	10396760
Malonic acid	10 mM	Alfa Aesar	11464523
NADP reduced (NADPH)	2 mM	Santa Cruz	sc-202725
Pantothenic acid	1 mM	SIGMA-ALDRICH	21210
Phthalic acid	10 $\mu$ M	SIGMA-ALDRICH	P39303
Proline	15 nM	Alfa Aesar	A10199.14
Quinolinic acid	5 mM	SIGMA-ALDRICH	160660
Riboflavin	1 $\mu$ M	Alfa Aesar	A11764
S-5-Adenosyl-L-Cysteine	100 $\mu$ M	SIGMA-ALDRICH	A7772

Shikimic acid	80 $\mu$ M	Acros Organics	10533491
Thymidine diphosphate (TDP)	2 mM	SIGMA-ALDRICH	T9375
Uridine diphosphate (UDP)	2 mM	SIGMA-ALDRICH	U4125
Phosphatidylglycerol 18:0 (PG (18:0))	2 mM	SIGMA-ALDRICH	840465P
alpha-linolenic acid	300 $\mu$ M	Santa Cruz	sc-205545
Dibenzyl malonate (DBnM)	10 mM	Alfa Aesar	A10844.09
Di-tert-butyl malonate (DBM)	10 mM	Apollo Scientific Ltd	OR55346
Dimethyl malonate (DMM)	10 mM	Alfa Aesar	A11007.22
Diethyl malonate (DEM)	10 mM	Acros Organics	10070760
Diisopropyl malonate (DPM)	10 mM	SIGMA-ALDRICH	411485
Meldrum's acid	10 mM	Activate Scientific	AS33739

1031 **Table 3: Metabolite and prodrug details**